Next Article in Journal
Impact of Routine Management Procedures on the Welfare of Suckling Piglets
Next Article in Special Issue
Histopathological and Immunohistochemical Evaluation of Canine Nerve Sheath Tumors and Proposal for an Updated Classification
Previous Article in Journal
Application of Hyperbaric Oxygen Therapy (HBOT) as a Healing Aid after Extraction of Incisors in the Equine Odontoclastic Tooth Resorption and Hypercementosis Syndrome
Article

European Mistletoe (Viscum album) Extract Is Cytotoxic to Canine High-Grade Astrocytoma Cells In Vitro and Has Additive Effects with Mebendazole

1
Auburn University Honors College, Cater Hall, 277 Thach Concourse, Auburn, AL 36849, USA
2
Department of Pathobiology, College of Veterinary Medicine, Auburn University, 166 Greene Hall, Auburn, AL 36849, USA
*
Author to whom correspondence should be addressed.
Current address: University of South Alabama Medical School, 307 University Blvd. N, Mobile, AL 36688, USA.
Academic Editors: Sara Belluco, Maria Teresa Mandara and Martí Pumarola
Vet. Sci. 2022, 9(1), 31; https://doi.org/10.3390/vetsci9010031
Received: 1 December 2021 / Revised: 4 January 2022 / Accepted: 11 January 2022 / Published: 15 January 2022
Malignant gliomas are associated with extremely poor clinical outcomes in both humans and dogs, and novel therapies are needed. Glioma-bearing canine patients may serve as promising preclinical models for human therapies, including complementary medicine. The objective of this study was to evaluate the effects of mistletoe extract (Viscum album) alone and in combination with mebendazole in an in vitro model of canine high-grade astrocytoma using the cell line SDT-3G. SDT-3G cells were exposed to a range of concentrations of mistletoe extract alone to obtain an IC50. In separate experiments, cells were exposed to mebendazole at a previously determined IC50 (0.03 µM) alone or in conjunction with varying concentrations of mistletoe extract to determine the additive effects. The IC50 for mistletoe alone was 5.644 ± 0.09 SD μg/mL. The addition of mistletoe at 5 μg/mL to mebendazole at 0.03 µM led to increased cell death compared to what would be expected for each drug separately. The cytotoxicity of mistletoe in vitro and its additive effect with mebendazole support future expanded in vitro and in vivo studies in dogs and supply early evidence that this may be a useful adjunct therapeutic agent for use in glioma-bearing dogs. To the authors’ knowledge, this is the first published report of Viscum album extract in canine glioma. View Full-Text
Keywords: canine; cancer; dog; glioma; glioblastoma; mistletoe; Viscum album; mebendazole canine; cancer; dog; glioma; glioblastoma; mistletoe; Viscum album; mebendazole
Show Figures

Figure 1

MDPI and ACS Style

Wright, A.; Watanabe, R.; Koehler, J.W. European Mistletoe (Viscum album) Extract Is Cytotoxic to Canine High-Grade Astrocytoma Cells In Vitro and Has Additive Effects with Mebendazole. Vet. Sci. 2022, 9, 31. https://doi.org/10.3390/vetsci9010031

AMA Style

Wright A, Watanabe R, Koehler JW. European Mistletoe (Viscum album) Extract Is Cytotoxic to Canine High-Grade Astrocytoma Cells In Vitro and Has Additive Effects with Mebendazole. Veterinary Sciences. 2022; 9(1):31. https://doi.org/10.3390/vetsci9010031

Chicago/Turabian Style

Wright, Anna, Rie Watanabe, and Jey W. Koehler. 2022. "European Mistletoe (Viscum album) Extract Is Cytotoxic to Canine High-Grade Astrocytoma Cells In Vitro and Has Additive Effects with Mebendazole" Veterinary Sciences 9, no. 1: 31. https://doi.org/10.3390/vetsci9010031

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop